ARTICLE | Company News
Capstone Therapeutics pulmonary, dermatology news
October 24, 2011 7:00 AM UTC
Capstone said it will reduce headcount by 14 (78%) to 4 to save cash while it searches for a partner for AZX100. The company will operate "virtually" by maintaining required regulatory and financial functions. The synthetic 24-amino acid peptide analog of heat shock protein 20 (Hsp20) is in Phase II testing to prevent scarring after arthroscopic shoulder surgery. The company also completed a preclinical trial of AZX100 to treat pulmonary fibrosis. Capstone has exclusive rights to AZX100 from AzERx Inc. (Phoenix, Ariz.) (see BioCentury, March 6, 2006). ...